Clinical Trial

Allo HSCT for High Risk Hemoglobinopathies

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.
Protocol Amendment History 1 change
minor Trial arms changed: 4 -> 5 2026-06-05
Trial Details
NCT Number NCT06872333
Lead Sponsor Masonic Cancer Center, University of Minnesota
Conditions Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Enrollment 62 participants
Start Date 2024-11-19
Primary Completion 2030-06-01 (estimated)
Study Completion 2032-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-04